Global cell and gene therapy CDMO adopts Valkit.ai for validation

A global cell and gene therapy contract development and manufacturing organization has selected Valkit.ai as its validation system of record across worldwide operations. The move replaces a first-generation digital validation tool as the company scales commercial manufacturing across multiple sites and regulated programs.

Why it matters: - The selection signals a shift from digitizing paper-based validation toward AI-native automation in a highly regulated part of life sciences. - A global CDMO running multiple sponsor programs, tech transfers, audits, and inspections needs faster validation workflows and stronger traceability. - The move could help reduce bottlenecks in commissioning, qualification, and computer system validation as manufacturing complexity grows.

What happened: - A global cell and gene therapy CDMO chose the Valkit.ai platform as its validation system of record across worldwide operations. - The company replaced a first-generation digital validation tool after re-evaluating its technology stack. - The CDMO operates five GMP sites across the United States, Europe, and Asia. - The company has manufactured more than 8,000 GMP batches. - The company manufactures multiple commercial cell and gene therapy products, including FDA-approved autologous therapies.

The details: - The company is a pure-play cell and gene therapy CDMO and multimodal biosafety testing organization. - The organization has more than 25 years of advanced therapy development and manufacturing expertise and more than 40 years in biosafety testing. - The company supports therapy developers from IND-enabling studies through commercial supply. - The site footprint spans CAR-T, TIL, iPSC, AAV, and lentiviral programs. - Valkit.ai will support Commissioning & Qualification, or C&Q, of manufacturing and testing infrastructure. - The platform will also manage the full Computer System Validation, or CSV, lifecycle from User Requirements Specification through Validation Summary Report. - Valkit.ai will provide Computer Software Assurance, or CSA, for regulated systems. - The platform includes AI-assisted validation documentation. - The platform includes native 21 CFR Part 11 and EU Annex 11 controls. - The platform includes automated risk-based traceability across every requirement and test. - The platform includes sponsor-level data isolation so client data is not exposed to third-party large language models. - Valkit.ai is a global SaaS provider headquartered in Indianapolis. - Valkit.ai is a pre-validated commercial off-the-shelf platform. - Valkit.ai is ISO 27001:2022 certified and 21 CFR Part 11 and EU Annex 11 compliant. - Independent customer studies cited by Valkit.ai show validation cycle times reduced by up to 85%, validation setup time cut from weeks to hours, documentation accuracy improved to 99.9%, and thousands of resource hours reclaimed annually. - Valkit.ai also says the platform serves pharmaceutical, biotechnology, and healthcare organizations with AI-powered digital validation and AI-powered risk assessment. - More information is available in the company's announcement. - Valkit.ai also shared a LinkedIn company page at social media profile.

Between the lines: - The company’s re-evaluation suggests first-generation validation software may not keep pace with multi-site advanced therapy manufacturing. - Valkit.ai is positioning its platform around eliminating manual work, not just converting paper workflows into software. - The deal adds to Valkit.ai's expansion in CRO and CDMO markets.

What's next: - Valkit.ai will be deployed globally across the CDMO's operations. - The platform will support ongoing validation work tied to new sponsor programs, equipment, and regulated systems. - The company is likely to use the system for future audits, inspections, and tech transfers as manufacturing expands.

The bottom line: - The deal underscores how advanced therapy manufacturers are looking for validation tools that can scale with faster, more complex, and more frequent regulatory demands.